PDC lung 01
Alternative Names: LR-19125; PDC*lung vaccine - PDC*line Pharma; PDC*lung01Latest Information Update: 17 Dec 2024
At a glance
- Originator PDC*line Pharma
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action CD8 positive T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 12 Dec 2024 Immunogenicity, adverse events and efficacy data from the phase I/II trial in Non-small cell lung cancer released by PDC*line Pharma
- 12 Dec 2024 PDC*line Pharma plans a phase IIb trial for Non-small cell lung cancer (First-line therapy, Late-stage disease, combination therapy) in 2026
- 08 Apr 2024 Efficacy, adverse event and immunogenicity data from the phase Ib/II PDC-LUNG-101 trial in Non-small-cell lung cancer released by PDC*line Pharma